X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (598) 598
humans (521) 521
female (398) 398
hpv-16 (327) 327
human papillomavirus (278) 278
cervical cancer (271) 271
hpv-16/18 as04-adjuvanted vaccine (221) 221
cancer (206) 206
papillomavirus infections (197) 197
oncology (182) 182
adult (169) 169
uterine cervical neoplasms - virology (159) 159
papillomavirus infections - prevention & control (153) 153
oncogene proteins, viral - genetics (137) 137
vaccination (137) 137
immunology (134) 134
virology (133) 133
vaccines (125) 125
middle aged (124) 124
papillomavirus infections - virology (124) 124
infection (120) 120
animals (119) 119
papillomavirus vaccines - immunology (106) 106
adolescent (105) 105
uterine cervical neoplasms - prevention & control (105) 105
young-women (100) 100
of-study analysis (99) 99
papillomavirus vaccines - administration & dosage (98) 98
hpv (96) 96
papillomaviruses (96) 96
human papillomavirus 16 - genetics (95) 95
papillomaviridae - genetics (94) 94
male (91) 91
human-papillomavirus type-16 (89) 89
intraepithelial neoplasia (89) 89
particle vaccine (88) 88
women (88) 88
cervical-cancer (86) 86
health aspects (86) 86
young adult (85) 85
analysis (84) 84
dna (82) 82
mice (81) 81
efficacy (80) 80
prevalence (79) 79
papillomavirus e7 proteins (76) 76
proteins (76) 76
aged (73) 73
oncogene proteins, viral - metabolism (73) 73
virus-like particles (73) 73
papillomavirus infections - complications (71) 71
papillomavirus infections - epidemiology (71) 71
papillomavirus infections - immunology (69) 69
cervical intraepithelial neoplasia (68) 68
hpv-16 e6 (68) 68
immunization (67) 67
infectious diseases (67) 67
biochemistry & molecular biology (64) 64
expression (64) 64
polymerase chain reaction (64) 64
research (64) 64
immunogenicity (61) 61
medicine, research & experimental (61) 61
obstetrics & gynecology (59) 59
papillomaviridae - isolation & purification (59) 59
blind patricia trial (58) 58
human papillomavirus 16 - immunology (58) 58
papillomaviridae - immunology (58) 58
biotechnology & applied microbiology (57) 57
follow-up (57) 57
gene expression (57) 57
child (56) 56
cervical intraepithelial neoplasia - virology (55) 55
oncogene proteins, viral - immunology (55) 55
uterine cervical neoplasms - pathology (55) 55
antibodies, viral - blood (54) 54
vaccine (52) 52
prevention (51) 51
risk factors (51) 51
microbiology (49) 49
lesions (47) 47
protein (47) 47
carcinoma (46) 46
double-blind (46) 46
molecular sequence data (46) 46
safety (46) 46
virus diseases (46) 46
dna, viral - genetics (45) 45
repressor proteins - genetics (45) 45
cell biology (44) 44
uterine cervical neoplasms - epidemiology (44) 44
cell line (43) 43
infections (43) 43
papillomavirus vaccines - adverse effects (43) 43
article (42) 42
human papillomavirus 16 - isolation & purification (42) 42
dna, viral - analysis (41) 41
genetic aspects (41) 41
randomized controlled-trial (41) 41
mice, inbred c57bl (40) 40
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (761) 761
Chinese (10) 10
Korean (9) 9
German (4) 4
Spanish (4) 4
French (3) 3
Polish (3) 3
Portuguese (3) 3
Japanese (2) 2
Croatian (1) 1
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Russian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Human Vaccines & Immunotherapeutics, ISSN 2164-5515, 07/2015, Volume 11, Issue 7, pp. 1689 - 1702
This observer-blind study (clinicaltrials.gov NCT01462357) compared the immunogenicity and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine... 
y, year(s) | AAHS, aluminum hydroxyphosphate sulfate | CI, confidence interval | PBMC, peripheral blood mononuclear cells | ELISA, enzyme-linked immunosorbent assay | M, month(s) | ELISPOT, enzyme-linked immunosorbent spot assay | human papillomavirus (HPV) vaccines | HPV-6/11/16/18(3D), 3-dose schedule of the HPV-6/11/16/18 vaccine | safety | ANOVA, analysis of variance | female adolescents | 50 | PBNA, pseudovirion-based neutralisation assay | GMT, geometric mean antibody titer | ED | 2D, 2-dose | AS04, Adjuvant System containing 50 µg 3-O-desacyl-4 ′-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 µg Al | CMI, cell-mediated immunity | 3D, 3-dose | ) | SAE, serious adverse event | immunogenicity | HPV, human papillomavirus | IgG, immunoglobulin G | TVC, total vaccinated cohort | 3 | ATP-I, according-to-protocol immunogenicity cohort | effective dose producing 50% response | HPV-16/18(2D), 2-dose schedule of the HPV-16/18 vaccine | IFNγ, interferon | VLP, virus-like particle | administration schedule | GMR, geometric mean titer ratio | EU, ELISA unit | HPV-6/11/16/18(2D), 2-dose schedule of the HPV-6/11/16/18 vaccine | pIMD, potential immune-mediated disease | Administration schedule | Safety | Immunogenicity | Human papillomavirus (HPV) vaccines | Female adolescents | PBNA | TVC | enzyme-linked immunosorbent spot assay | pIMD | CLINICAL-TRIAL | potential immune-mediated disease | OF-STUDY ANALYSIS | ELISA unit | IMMUNOLOGY | NEUTRALIZATION ASSAY | 18(3D) | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | geometric mean antibody titer | BLIND PATRICIA TRIAL | CMI | 2-dose | pseudovirion-based neutralisation assay | AS04 | CERVICAL-CANCER | GMR | PBMC | GMT | MEMORY B-CELLS | according-to-protocol immunogenicity cohort | AAHS | PARTICLE VACCINE | SAE | human papillomavirus | HPV VACCINE | ELISA | ATP-I | month(s) | virus-like particle | 3-dose | geometric mean titer ratio | IgG | 2-dose schedule of the HPV-16 | HPV | 18 vaccine | IFN | 18(2D) | CD154 EXPRESSION | analysis of variance | ANOVA | serious adverse event | total vaccinated cohort | year(s) | ED50 | VLP | YOUNG-WOMEN | Adjuvant System containing 50 mu g 3-O-desacyl-4-monophosphoryl lipid A (MPL) adsorbed on aluminum salt (500 mu g Al3+) | peripheral blood mononuclear cells | aluminum hydroxyphosphate sulfate | immunoglobulin G | 3-dose schedule of the HPV-6 | HPV-16 | HPV-6 | 2-dose schedule of the HPV-6 | interferon | ELISPOT | enzyme-linked immunosorbent assay | confidence interval | cell-mediated immunity | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - adverse effects | Adjuvants, Immunologic - administration & dosage | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - immunology | Vaccine Potency | Humans | Alphapapillomavirus - immunology | Antibodies, Viral - blood | Immunity, Humoral | Time Factors | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 - administration & dosage | Papillomavirus Infections - prevention & control | Adolescent | Papillomavirus Vaccines - adverse effects | Female | Immunization Schedule | Papillomavirus Vaccines - immunology | Child | Immunity, Cellular | Papillomavirus Vaccines - administration & dosage | Antibodies, Neutralizing - blood | Index Medicus | Medical and Health Sciences | Basic Medicine | Medicinsk bioteknologi | Medical Biotechnology | Medicin och hälsovetenskap | Immunologi inom det medicinska området | Immunology in the medical area | Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy) | Medicinsk bioteknologi (med inriktning mot cellbiologi (inklusive stamcellsbiologi), molekylärbiologi, mikrobiologi, biokemi eller biofarmaci) | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Journal Article
Human Vaccines & Immunotherapeutics, ISSN 2164-5515, 08/2014, Volume 10, Issue 8, pp. 2147 - 2162
HPV-023 (NCT00518336; ClinicalTrial.gov) is a long-term follow-up of an initial double-blind, randomized (1:1), placebo-controlled study (HPV-001, NCT00689741)... 
human papillomavirus (HPV) | HPV-16/18 AS04-adjuvanted vaccine | safety | long-term protection | cervical cancer | pre-cancer | efficacy | immunogenicity | Immunogenicity | Long-term protection | Efficacy | Human papillomavirus (HPV) | Safety | Pre-cancer | Cervical cancer | HUMAN-PAPILLOMAVIRUS TYPE-16 | OF-STUDY ANALYSIS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | NEUTRALIZATION ASSAY | PARTICLE VACCINE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | INVASIVE CERVICAL-CANCER | BLIND PATRICIA TRIAL | POOLED ANALYSIS | ANTIBODY-RESPONSE | YOUNG-WOMEN | Human papillomavirus 18 - immunology | Follow-Up Studies | Humans | DNA, Viral - analysis | Neutralization Tests | Human papillomavirus 16 - immunology | Antibodies, Viral - blood | Young Adult | Human papillomavirus 16 - isolation & purification | Brazil | Papillomavirus Vaccines - adverse effects | Adult | Female | Papillomavirus Vaccines - administration & dosage | Enzyme-Linked Immunosorbent Assay | Uterine Cervical Neoplasms - prevention & control | Treatment Outcome | Vaginal Smears | Drug-Related Side Effects and Adverse Reactions - epidemiology | Human papillomavirus 18 - isolation & purification | Papillomavirus Infections - prevention & control | Adolescent | Histocytochemistry | Papillomavirus Vaccines - immunology | DNA, Viral - genetics | Antibodies, Neutralizing - blood | Index Medicus
Journal Article
CANCERS, ISSN 2072-6694, 04/2019, Volume 11, Issue 4, p. 473
The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is rising in high-income countries, including Australia. Increasing evidence... 
VIRAL LOAD | HEAD | CAVITY | RISK | HUMAN-PAPILLOMAVIRUS | PREVALENCE | saliva | ORAL HPV INFECTION | ONCOLOGY | NEOPLASIA | human papillomavirus | HPV-16 viral load | SQUAMOUS-CELL CARCINOMA | oropharyngeal cancer | HPV-16 integration
Journal Article
Journal of Medical Virology, ISSN 0146-6615, 09/2004, Volume 74, Issue 1, pp. 117 - 126
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 05/2001, Volume 283, Issue 3, pp. 668 - 673
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 2008, Volume 371, Issue 4, pp. 684 - 688
Epidemiological and experimental studies have shown that high-risk human papillomaviruses (HPVs) are the causative agents of cervical cancer worldwide, and... 
HPV-16 | E5 oncoprotein | Karyopherin β3 | karyopherin β3
Journal Article
BJOG: An International Journal of Obstetrics & Gynaecology, ISSN 1470-0328, 01/2015, Volume 122, Issue 1, pp. 107 - 118
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 04/2016, Volume 17, Issue 3, pp. 1093 - 1096
Journal Article
VACCINE, ISSN 0264-410X, 08/2006, Volume 24, pp. 26 - 34
Geographical widespread data on human papillomavirus (HPV) type-distribution are essential for estimating the impact of HPV-16/18 vaccines on cervical cancer... 
MEDICINE, RESEARCH & EXPERIMENTAL | DIAGNOSIS | INFECTIONS | CANCER WORLDWIDE | METAANALYSIS | MANAGEMENT | HUMAN-PAPILLOMAVIRUS TYPE-16 | HPV-16/18 fraction | RISK | IMMUNOLOGY | geographical heterogeneity | HPV typing | POLYMERASE-CHAIN-REACTION | DNA | VETERINARY SCIENCES | PRECANCER
Journal Article
Oncology Reports, ISSN 1021-335X, 12/2010, Volume 24, Issue 6, pp. 1599 - 1604
Journal Article
PATHOLOGE, ISSN 0172-8113, 05/2018, Volume 39, Issue 3, pp. 269 - 279
Of the numerous aspects involved in the diagnosis, treatment, and follow-up of cervical uterine precursor lesions, epidemiology, virology, cytology, human... 
Biomarkers | HPV-16 | Ki-67 antigen | PATHOLOGY | Cytology | HPV DNA test
Journal Article
Pathologe, ISSN 0172-8113, 05/2018, Volume 39, Issue 3, pp. 269 - 279
Journal Article
International Journal Bioautomation, ISSN 1314-1902, 2014, Volume 18, Issue 4, pp. 315 - 324
Cervical cancer caused by Human papillomavirus (HPV) is one of the leading causes of cancer mortality in women worldwide, particularly in the developing... 
HPV-16 | Plant ligands | Docking | Cancer
Journal Article
Journal of Adolescent Health, ISSN 1054-139X, 02/2012, Volume 50, Issue 2, pp. 187 - 194
Purpose: Long-term immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine when administered to adolescent girls was... 
Human papillomavirus | Immunogenicity | HPV-16/18 AS04-adjuvanted vaccine | Adolescent | Female | Long-term | Safety | Monophosphoryl lipid A | Cervical cancer
Journal Article
JOURNAL OF VIROLOGY, ISSN 0022-538X, 02/2013, Volume 87, Issue 3, pp. 1586 - 1595
Cervical cancer develops through the combined activities of the human papillomavirus (HPV) E6 and E7 oncoproteins. A defining characteristic of E6 oncoproteins... 
LUNG-CANCER | VIROLOGY | THERAPEUTIC TARGET | HPV-16 E6 | ANCHORAGE-INDEPENDENT GROWTH | CERVICAL-CANCER | DISCS LARGE PROTEIN | TYPE-16 E6 | DIFFERENTIAL REGULATION | UP-REGULATION | CELL POLARITY
Journal Article